BPMC - Blueprint Medicines Corporation

-

$undefined

N/A

(N/A)

Blueprint Medicines Corporation NasdaqGS:BPMC Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Location: 45 Sidney Street, Cambridge, MA, 02139, United States | Website: https://www.blueprintmedicines.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

6.682B

Cash

576.2M

Avg Qtr Burn

-36.39M

Short % of Float

9.44%

Insider Ownership

0.87%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

AYVAKIT (avapritinib) Details
PDGFRA mutant GIST (Gastrointestinal Stromal Tumors)

Approved

Quarterly sales

GAVRETO (parlsetinib) Details
Non-small cell lung carcinoma, Thyroid cancer, Cancer, Solid tumor/s

Approved

Quarterly sales

BLU-808 Details
Chronic urticaria, CSU/CInDu, allergic rhinitis/allergic conjunctivitis

Phase 2

Initiation

BLU-945 +/- osimertinib Details
Cancer, Solid tumor/s, Non-small cell lung carcinoma

Phase 1/2

Update

BLU-451 Details
Non-small cell lung carcinoma, Cancer, Solid tumor/s

Phase 1/2

Update

BLU-222 (CDK12) Details
Breast cancer, Cancer

Phase 1/2

Update

Elenestinib Details
Systemic Mastocytosis

Phase 1

Update